Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the three months ended September 30, 2026.
Atea Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the three months ended September 30, 2026
- Press release contains the substantive financial results and accompanying company updates, filed as Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- C-BEYOND met primary and secondary endpoints, with BEM/RZR SVR 93.91% versus SOF/VEL 94.75% in 905 patients
- C-FORWARD fully enrolled with more than 880 patients across 17 countries, topline results expected early 2027
- NDA submission targeted for mid-2027, contingent on C-FORWARD results supporting pan-genotypic HCV use
- Hercules Capital facility provides up to $200 million, including $65 million drawn at closing and potential additional funding of $135 million
- Cash and investments $191.2 million versus $301.8 million at December 31, 2025, with planned operations funded into mid-2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atea Pharmaceuticals, Inc. 8-K filings
Get the next AVIR 8-K as it lands
Follow AVIR for push alerts, or ask the research agent what this filing means.